Drabløs Finn, Feyzi Emadoldin, Aas Per Arne, Vaagbø Cathrine B, Kavli Bodil, Bratlie Marit S, Peña-Diaz Javier, Otterlei Marit, Slupphaug Geir, Krokan Hans E
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, N-7489 Trondheim, Norway.
DNA Repair (Amst). 2004 Nov 2;3(11):1389-407. doi: 10.1016/j.dnarep.2004.05.004.
Alkylation lesions in DNA and RNA result from endogenous compounds, environmental agents and alkylating drugs. Simple methylating agents, e.g. methylnitrosourea, tobacco-specific nitrosamines and drugs like temozolomide or streptozotocin, form adducts at N- and O-atoms in DNA bases. These lesions are mainly repaired by direct base repair, base excision repair, and to some extent by nucleotide excision repair (NER). The identified carcinogenicity of O(6)-methylguanine (O(6)-meG) is largely caused by its miscoding properties. Mutations from this lesion are prevented by O(6)-alkylG-DNA alkyltransferase (MGMT or AGT) that repairs the base in one step. However, the genotoxicity and cytotoxicity of O(6)-meG is mainly due to recognition of O(6)-meG/T (or C) mispairs by the mismatch repair system (MMR) and induction of futile repair cycles, eventually resulting in cytotoxic double-strand breaks. Therefore, inactivation of the MMR system in an AGT-defective background causes resistance to the killing effects of O(6)-alkylating agents, but not to the mutagenic effect. Bifunctional alkylating agents, such as chlorambucil or carmustine (BCNU), are commonly used anti-cancer drugs. DNA lesions caused by these agents are complex and require complex repair mechanisms. Thus, primary chloroethyl adducts at O(6)-G are repaired by AGT, while the secondary highly cytotoxic interstrand cross-links (ICLs) require nucleotide excision repair factors (e.g. XPF-ERCC1) for incision and homologous recombination to complete repair. Recently, Escherichia coli protein AlkB and human homologues were shown to be oxidative demethylases that repair cytotoxic 1-methyladenine (1-meA) and 3-methylcytosine (3-meC) residues. Numerous AlkB homologues are found in viruses, bacteria and eukaryotes, including eight human homologues (hABH1-8). These have distinct locations in subcellular compartments and their functions are only starting to become understood. Surprisingly, AlkB and hABH3 also repair RNA. An evaluation of the biological effects of environmental mutagens, as well as understanding the mechanism of action and resistance to alkylating drugs require a detailed understanding of DNA repair processes.
DNA和RNA中的烷基化损伤源于内源性化合物、环境因子及烷基化药物。简单的甲基化剂,如甲基亚硝基脲、烟草特异性亚硝胺以及替莫唑胺或链脲佐菌素等药物,会在DNA碱基的N原子和O原子处形成加合物。这些损伤主要通过直接碱基修复、碱基切除修复进行修复,在一定程度上也可通过核苷酸切除修复(NER)进行修复。已确定的O(6)-甲基鸟嘌呤(O(6)-meG)的致癌性很大程度上是由其错配编码特性导致的。该损伤引发的突变可通过一步修复碱基的O(6)-烷基鸟嘌呤-DNA烷基转移酶(MGMT或AGT)来预防。然而,O(6)-meG的遗传毒性和细胞毒性主要是由于错配修复系统(MMR)识别O(6)-meG/T(或C)错配并诱导无效修复循环,最终导致细胞毒性双链断裂。因此,在AGT缺陷背景下MMR系统的失活会导致对O(6)-烷基化剂杀伤作用的抗性,但不会导致对诱变作用的抗性。双功能烷基化剂,如苯丁酸氮芥或卡莫司汀(BCNU),是常用的抗癌药物。这些药物引起的DNA损伤较为复杂,需要复杂的修复机制。因此,O(6)-G处的初级氯乙烷基加合物由AGT修复,而次级具有高度细胞毒性的链间交联(ICL)则需要核苷酸切除修复因子(如XPF-ERCC1)进行切割,并通过同源重组来完成修复。最近,大肠杆菌蛋白AlkB及其人类同源物被证明是氧化脱甲基酶,可修复具有细胞毒性的1-甲基腺嘌呤(1-meA)和3-甲基胞嘧啶(3-meC)残基。在病毒、细菌和真核生物中发现了许多AlkB同源物,包括八种人类同源物(hABH1-8)。它们在亚细胞区室中具有不同的定位,其功能才刚刚开始被了解。令人惊讶的是,AlkB和hABH3也可修复RNA。评估环境诱变剂的生物学效应以及了解烷基化药物的作用机制和抗性需要详细了解DNA修复过程。